Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 489

1.

Therapeutic Targeting of the Colorectal Tumor Stroma.

Fridman WH, Miller I, Sautès-Fridman C, Byrne AT.

Gastroenterology. 2019 Oct 14. pii: S0016-5085(19)41442-X. doi: 10.1053/j.gastro.2019.09.045. [Epub ahead of print]

PMID:
31622621
2.

Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial.

Di Giacomo AM, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, Giannarelli D, Petiprez F, Lacroix L, Valente M, Cutaia O, Fazio C, Amato G, Lazzeri A, Monterisi S, Miracco C, Coral S, Anichini A, Bock C, Nemc A, Oganesian A, Lowder JN, Azab M, Fridman WH, Sautes-Fridman C, Trajanoski Z, Maio M.

Clin Cancer Res. 2019 Sep 17. pii: clincanres.1335.2019. doi: 10.1158/1078-0432.CCR-19-1335. [Epub ahead of print]

PMID:
31530631
3.

Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology.

Sturm G, Finotello F, Petitprez F, Zhang JD, Baumbach J, Fridman WH, List M, Aneichyk T.

Bioinformatics. 2019 Jul 15;35(14):i436-i445. doi: 10.1093/bioinformatics/btz363.

4.

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.

Le Cesne A, Marec-Berard P, Blay JY, Gaspar N, Bertucci F, Penel N, Bompas E, Cousin S, Toulmonde M, Bessede A, Fridman WH, Sautes-Fridman C, Kind M, Le Loarer F, Pulido M, Italiano A.

Eur J Cancer. 2019 Sep;119:151-157. doi: 10.1016/j.ejca.2019.07.018. Epub 2019 Aug 21.

PMID:
31442817
5.

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25.

PMID:
31229459
6.

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.

Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec'h BL, Giraldo NA, Merle NS, Sun CM, Verkarre V, Validire P, Selves J, Lacroix L, Delfour O, Vandenberghe I, Thuilliez C, Keddani S, Sakhi IB, Barret E, Ferré P, Corvaïa N, Passioukov A, Chetaille E, Botto M, de Reynies A, Oudard SM, Mejean A, Cathelineau X, Sautès-Fridman C, Fridman WH.

Cancer Immunol Res. 2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4.

PMID:
31164356
7.

Tertiary lymphoid structures in the era of cancer immunotherapy.

Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH.

Nat Rev Cancer. 2019 Jun;19(6):307-325. doi: 10.1038/s41568-019-0144-6. Review.

PMID:
31092904
8.

[From the time in the wilderness to the Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo: the Long March of cancer immunotherapy].

Fridman WH, Teillaud JL.

Med Sci (Paris). 2019 Apr;35(4):367-373. doi: 10.1051/medsci/2019074. Epub 2019 Apr 30. French. No abstract available.

PMID:
31038116
9.

Revisiting immune escape in colorectal cancer in the era of immunotherapy.

Ijsselsteijn ME, Petitprez F, Lacroix L, Ruano D, van der Breggen R, Julie C, Morreau H, Sautès-Fridman C, Fridman WH, de Miranda NFDCC.

Br J Cancer. 2019 Apr;120(8):815-818. doi: 10.1038/s41416-019-0421-x. Epub 2019 Mar 13.

10.

Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.

Giraldo NA, Peske JD, Sautès-Fridman C, Fridman WH.

Virchows Arch. 2019 Apr;474(4):463-474. doi: 10.1007/s00428-018-02517-1. Epub 2019 Jan 10. Review.

PMID:
30631935
11.

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R.

Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18.

PMID:
30564889
12.

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, Salkova E, Rob L, Kodet R, Goc J, Sautes-Fridman C, Fridman WH, Ryska A, Galluzzi L, Spisek R, Fucikova J.

J Immunother Cancer. 2018 Dec 4;6(1):139. doi: 10.1186/s40425-018-0446-3.

13.

The clinical role of the TME in solid cancer.

Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C.

Br J Cancer. 2019 Jan;120(1):45-53. doi: 10.1038/s41416-018-0327-z. Epub 2018 Nov 9. Review.

PMID:
30413828
14.

Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine.

Petitprez F, Sun CM, Lacroix L, Sautès-Fridman C, de Reyniès A, Fridman WH.

Front Oncol. 2018 Sep 25;8:390. doi: 10.3389/fonc.2018.00390. eCollection 2018. Review.

15.

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer.

Weinstein AM, Giraldo NA, Petitprez F, Julie C, Lacroix L, Peschaud F, Emile JF, Marisa L, Fridman WH, Storkus WJ, Sautès-Fridman C.

Cancer Immunol Immunother. 2019 Jan;68(1):109-120. doi: 10.1007/s00262-018-2259-0. Epub 2018 Oct 12.

PMID:
30315348
16.

Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.

Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, Luciani A, Amaddeo G, Derman J, Charpy C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C.

J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.

PMID:
30213589
17.

From Cancer Immune Surveillance to Cancer Immunoediting: Birth of Modern Immuno-Oncology.

Fridman WH.

J Immunol. 2018 Aug 1;201(3):825-826. doi: 10.4049/jimmunol.1800827. No abstract available.

18.

Immune-based identification of cancer patients at high risk of progression.

Vano YA, Petitprez F, Giraldo NA, Fridman WH, Sautès-Fridman C.

Curr Opin Immunol. 2018 Apr;51:97-102. doi: 10.1016/j.coi.2018.03.005. Epub 2018 Mar 16. Review.

PMID:
29554496
19.

Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum.

Yagi H, Takakura D, Roumenina LT, Fridman WH, Sautès-Fridman C, Kawasaki N, Kato K.

Sci Rep. 2018 Feb 9;8(1):2719. doi: 10.1038/s41598-018-21145-y.

20.

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.

Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.

21.

Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.

Kerdivel G, Chesnais V, Becht E, Toma A, Cagnard N, Dumont F, Rousseau A, Fenaux P, Chevret S, Chapuis N, Boeva V, Fridman WH, Fontenay M, Kosmider O.

Leukemia. 2018 Feb;32(2):558-562. doi: 10.1038/leu.2017.305. Epub 2017 Oct 3. No abstract available.

PMID:
28972593
22.

Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies.

Petitprez F, Vano YA, Becht E, Giraldo NA, de Reyniès A, Sautès-Fridman C, Fridman WH.

Cancer Immunol Immunother. 2018 Jun;67(6):981-988. doi: 10.1007/s00262-017-2058-z. Epub 2017 Sep 7. Review.

PMID:
28884365
23.

PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.

Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, Briganti A, Doglioni C, Bellone M.

Eur Urol Focus. 2019 Mar;5(2):192-196. doi: 10.1016/j.euf.2017.05.013. Epub 2017 Jun 21.

PMID:
28753812
24.

The immune contexture in cancer prognosis and treatment.

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G.

Nat Rev Clin Oncol. 2017 Dec;14(12):717-734. doi: 10.1038/nrclinonc.2017.101. Epub 2017 Jul 25. Review.

PMID:
28741618
25.

Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice.

Casuscelli J, Vano YA, Fridman WH, Hsieh JJ.

Kidney Cancer. 2017 Jul 26;1(1):3-13. doi: 10.3233/KCA-170008. Review.

26.

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.

Giraldo NA, Becht E, Vano Y, Petitprez F, Lacroix L, Validire P, Sanchez-Salas R, Ingels A, Oudard S, Moatti A, Buttard B, Bourass S, Germain C, Cathelineau X, Fridman WH, Sautès-Fridman C.

Clin Cancer Res. 2017 Aug 1;23(15):4416-4428. doi: 10.1158/1078-0432.CCR-16-2848. Epub 2017 Feb 17.

27.

Historique de l’immunothérapie. Changement de paradigme ?

Fridman WH.

Bull Cancer. 2016 Nov;103 Suppl 1:S122-S126. doi: 10.1016/S0007-4551(16)30368-X. French.

PMID:
28057174
28.

Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Dec 1;17(1):249. No abstract available.

29.

Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.

Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A.

Genome Biol. 2016 Oct 20;17(1):218. Erratum in: Genome Biol. 2016 Dec 1;17 (1):249.

30.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

31.

Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.

Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, Dieu-Nosjean MC.

Front Immunol. 2016 Oct 3;7:407. eCollection 2016. Review.

32.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Mar 10;5(6):e1149674. doi: 10.1080/2162402X.2016.1149674. eCollection 2016 Jun. Review.

33.

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.

Iribarren K, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Špíšek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Sep 2;5(3):e1088631. eCollection 2016 Mar. Review.

34.

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.

Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C.

Immunol Rev. 2016 May;271(1):260-75. doi: 10.1111/imr.12405. Review.

PMID:
27088920
35.

Trial Watch-Immunostimulation with cytokines in cancer therapy.

Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1115942. eCollection 2016 Feb. Review.

36.

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy.

Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, Selves J, Sautès-Fridman C, Laurent-Puig P, Fridman WH.

Clin Cancer Res. 2016 Aug 15;22(16):4057-66. doi: 10.1158/1078-0432.CCR-15-2879. Epub 2016 Mar 18.

37.

[History of immunotherapy. Paradigm change?]

Fridman WH.

Bull Cancer. 2016 Mar 11. pii: S0007-4551(16)00034-5. doi: 10.1016/j.bulcan.2016.01.013. [Epub ahead of print] French. No abstract available.

PMID:
26976507
38.

Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.

Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-Puig P, Zucman-Rossi J, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Adv Immunol. 2016;130:95-190. doi: 10.1016/bs.ai.2015.12.002. Epub 2016 Jan 29. Review.

PMID:
26923001
39.

Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.

Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I.

Cancer Res. 2016 Apr 1;76(7):1746-56. doi: 10.1158/0008-5472.CAN-15-1142. Epub 2016 Feb 3.

40.

Cancer immune contexture and immunotherapy.

Becht E, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH.

Curr Opin Immunol. 2016 Apr;39:7-13. doi: 10.1016/j.coi.2015.11.009. Epub 2015 Dec 17. Review.

PMID:
26708937
41.

TLS in Tumors: What Lies Within.

Sautès-Fridman C, Fridman WH.

Trends Immunol. 2016 Jan;37(1):1-2. doi: 10.1016/j.it.2015.12.001. Epub 2015 Dec 17.

PMID:
26706045
42.

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH.

Oncoimmunology. 2015 Aug 7;4(12):e1049804. eCollection 2015 Dec.

43.

Integrating tumor microenvironment with cancer molecular classifications.

Becht E, de Reyniès A, Fridman WH.

Genome Med. 2015 Nov 14;7(1):115. doi: 10.1186/s13073-015-0241-4.

44.

Trial Watch: Adoptive cell transfer for oncological indications.

Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 May 5;4(11):e1046673. eCollection 2015 Nov. Review.

45.

From mice to humans: developments in cancer immunoediting.

Teng MW, Galon J, Fridman WH, Smyth MJ.

J Clin Invest. 2015 Sep;125(9):3338-46. doi: 10.1172/JCI80004. Epub 2015 Aug 4. Review.

46.

Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?

Kroemer G, Galluzzi L, Zitvogel L, Fridman WH.

Oncoimmunology. 2015 Jun 5;4(7):e1058597. eCollection 2015 Jul.

47.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

48.

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008814. eCollection 2015 Apr. Review.

49.

The immune response in cancer: from immunology to pathology to immunotherapy.

Giraldo NA, Becht E, Vano Y, Sautès-Fridman C, Fridman WH.

Virchows Arch. 2015 Aug;467(2):127-35. doi: 10.1007/s00428-015-1787-7. Epub 2015 Jun 16. Review.

PMID:
26077464
50.

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Feb 3;4(1):e985940. eCollection 2015 Jan. Review.

Supplemental Content

Loading ...
Support Center